Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Among patients with smoldering multiple myeloma at high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology